Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
- Author(s)
- Cummins, K; Gill, S;
- Journal Title
- Hematology/Oncology Clinics of North America
- Publication Type
- Review
- Abstract
- Up to 30% of patients with acute myeloid leukemia (AML) who undergo chimeric antigen receptor (CAR) T-cell therapy have evidence of response, although trials are highly heterogeneous. These responses are rarely deep or durable. CD123, CD33, and CLL-1 have emerged as the most common targets for CAR T cells in AML. CAR T cells against myeloid antigens cause myeloablation as well as cytokine release syndrome, although neurotoxicity is rarely seen. Future efforts should focus on AML-specific antigen discovery or engineering, and on further enhancing the activity of CAR T cells.
- Publisher
- Elsevier
- Keywords
- Acute myeloid leukemia; CAR T cells; Crs; Cellular immunotherapy; Myeloablation
- Department(s)
- Clinical Haematology
- PubMed ID
- 37442676
- Publisher's Version
- https://doi.org/10.1016/j.hoc.2023.06.004
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-10-17 06:55:51
Last Modified: 2024-07-09 05:19:56